恩瑞格效果怎样呢？

Precautions: First, the main ingredient of Enriga may cause a rash. Although the rash usually disappears automatically without the need to adjust the dose or stop the medication, there are some patients whose condition is more serious or will continue to occur, so the medication must be stopped in time. Second, after taking this medicine, the patient's vision or hearing may be affected. Third, this medicine should be taken 30 minutes before meals. Fourth, the time of taking this medicine must be the same every day, so that the effect of the medicine will be better. Patients and friends should pay more attention to these precautions. What we want to know today is what is the effect of Enrig?

Currently, iron-removing drugs commonly used in clinical practice include ferroxamine and Enrego. Ferrioxamine is the first-generation iron-removing agent, but it requires intravenous infusion for 8 to 12 hours a day and 5 to 7 days a week. The patient's compliance will be greatly reduced, because poor compliance will lead to poor clinical efficacy. Another commonly used iron-removing drug is the new generation of Enrige dispersible tablets, which can adsorb and chelate the most harmful free iron in the patient's body. Enrig is more convenient and has higher patient compliance. EPIC is currently the largest prospective, open, single-group, global multi-center clinical study designed for patients with iron overload. A total of 341 MDS patients were enrolled, and it could reduce serum ferritin by an average of 372 μg/L in 3 months.

DFS (ICL670), DFS, is currently the only oral iron chelator developed by Novartis. It was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Enrig was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and above with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved the new indication of Enriga for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) aged 10 years and above.

The results of a single-arm, multi-center, prospective clinical study involving 64 AA patients with transfusion-related iron overload confirmed the effectiveness and safety of Enrig in reducing patients' ferritin levels. A prospective, observational study in my country using liver, pancreas, and heart as monitoring indicators confirmed that Enrig can improve organ function in patients with iron overload. The results of the TELESTO study released at the ASH 2018 meeting also proved that Enrige continuously reduces serum ferritin levels, while reducing the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%.

The above is the content of the effect, I hope it can help you!